The Medical Advisor

Abstract Background: Head and neck cancers (HNC), predominantly squamous cell carcinomas, remain a significant global health burden with substantial morbidity and mortality, particularly in advanced or recurrent disease. Despite progress in surgery, radiotherapy, and immunotherapy, treatment resistance and toxicity continue to limit long-term outcomes. Repurposed antiparasitic agents, including ivermectin and fenbendazole, have gained attention for their potential anticancer properties based on preclinical evidence and emerging anecdotal clinical observations. Objective: To evaluate the biological rationale, preclinical evidence, and real-world anecdotal data supporting the use of ivermectin and fenbendazole in head and neck cancers, and to contextualize these findings within current oncologic treatment paradigms. Methods: A narrative synthesis was conducted integrating mechanistic studies, preclinical oncology literature, and publicly available case reports involving ivermectin and fe...